Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
combination therapy
Pharma
Jazz touts Ziihera as HER2 agent of choice in stomach cancer
“What is clear is that we have found a better way to target HER2,” an ASCO-invited expert said, referring to Ziihera as better than Herceptin.
Angus Liu
Jan 6, 2026 3:25pm
Incyte to seek FDA approval for Monjuvi in front-line DLBCL
Jan 5, 2026 10:40am
Keytruda, Padcev keep winning streak in bladder cancer
Dec 17, 2025 9:53am
ASH: J&J pressures CAR-T with Tecvayli combo in 2L myeloma
Dec 9, 2025 7:30am
Merck partner Kelun touts ph. 3 win for ADC in first-line NSCLC
Nov 24, 2025 10:56am
Merck, Eisai call it quits on Keytruda-Lenvima in liver cancer type
Oct 29, 2025 11:32am
